ArticleCureus2026
Naloxone Use and Outcomes in Prehospital and Emergency Department Care.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Opioid toxicity remains a major public health concern in Canada, which is driven by potent synthetic opioids such as fentanyl. Naloxone is the antidote for opioid toxicity and can be given in a variety of routes and dosages. Naloxone is administered by bystanders, first responders, emergency medical services (EMS), and emergency physicians. Despite its widespread use, there are limited local data on its administration in the prehospital and emergency department (ED) settings, as well as on its associated outcomes. Materials and methods This was a retrospective review study of patients presenting to a tertiary care ED in 2024 who had a discharge diagnostic code "poison narcotics" and received naloxone. Prehospital and ED charts were reviewed to collect demographics, naloxone dose, route, number of doses, reversal success, disposition, and opioid agonist therapy (OAT) initiation and referral. Descriptive statistics were used, and Fisher's exact test was used to compare outcomes between single and multiple naloxone doses. Results Thirty-three patients met the inclusion criteria (mean age 40.4 years; 33.3% female). Naloxone was administered prehospital in 93.9% of cases, with 60.6% receiving naloxone prior to EMS arrival. Prehospital reversal success was 83.9%. EMS administered naloxone to 54.5% of patients at various dosages and routes. Seven patients required naloxone in the ED, and two needed an ICU admission. There were no deaths. Only 6.25% of patients were started on or referred for OAT, none directly following opioid toxicity reversal. There was no significant difference in reversal success or disposition between those who received single versus multiple doses of naloxone. Conclusions Most cases were successfully reversed prior to ED arrival, and many were managed by first responders and bystanders, highlighting the importance of public education and access to intranasal naloxone. Low rates of OAT initiation underscore the need to prevent barriers to treatment following an ED visit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.